...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Neuroimmunology: Official Bulletin of the Research Committee on Neuroimmunology of the World Federation of Neurology >A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein.
【24h】

A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein.

机译：神经丝重链蛋白的高度灵敏的化学发光免疫测定。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The loss of neurological function is closely related to axonal damage. Neurofilament subunits are concentrated in neurons and axons and have emerged as promising biomarkers for neurodegeneration. Electrochemiluminescence (ECL) based assays are known to be of superior sensitivity and require less sample volume than conventional ELISAs. METHODS: We developed an ECL based solid-phase sandwich immunoassay to measure the neurofilament heavy chain protein (NfH(SMI35)) in CSF. We employed commercially available antibodies as previously used in a conventional ELISA (Petzold et al., 2003; Petzold and Shaw, 2007). The optimised and validated assay was applied in a reference cohort and defined patient groups. RESULTS: Analytical sensitivity (background plus three SD) of our assay was 2.4 pg/ml. The mean intra-assay coefficient of variation (CV) was 4.8% and the inter-assay CV 8.4%. All measured control and patient samples produced signals well above background. Patients with multiple sclerosis (MS) (median 46.2 pg/ml, n=95), amyotrophic lateral sclerosis (ALS) (160.1 pg/ml, n=50), mild cognitive impairment/Alzheimer's disease (MCI/AD) (65.6 pg/ml, n=20), Guillain-Barre syndrome (GBS) (91.0 pg/ml, n=20) or subarachnoid hemorrhage (SAH) (345.0 pg/ml, n=20) had higher CSF NfH(SMI35) values than the reference cohort (27.1 pg/ml, n=73, p<0.0001 for each comparison). CONCLUSION: The new ECL based assay for NfH(SMI35) in CSF is superior in terms of sensitivity, precision and accuracy to previously published methods (Petzold et al., 2003; Shaw et al., 2005; Teunissen et al., 2009). The improved performance and small sample volume requirement qualify this method in experimental settings and clinical trials designed to perform a number of tests on limited amounts of material.
机译：背景：神经功能的丧失与轴突损伤密切相关。神经丝亚单位集中在神经元和轴突中，并已成为有希望的神经变性生物标志物。已知基于电化学发光（ECL）的测定法具有较高的灵敏度，并且比常规ELISA所需的样品量更少。方法：我们开发了一种基于ECL的固相夹心免疫测定方法，用于测定CSF中的神经丝重链蛋白（NfH（SMI35））。我们采用了以前在常规ELISA中使用的市售抗体（Petzold等，2003; Petzold和Shaw，2007）。经过优化和验证的测定应用于参考人群和确定的患者组。结果：本试验的分析灵敏度（背景加三个SD）为2.4 pg / ml。批内平均变异系数（CV）为4.8％，批间间变异系数为8.4％。所有测得的对照和患者样品产生的信号都远高于背景。多发性硬化症（MS）（中位数46.2 pg / ml，n = 95），肌萎缩性侧索硬化症（ALS）（160.1 pg / ml，n = 50），轻度认知障碍/阿尔茨海默氏病（MCI / AD）（65.6 pg） / ml，n = 20），格林-巴利综合征（GBS）（91.0 pg / ml，n = 20）或蛛网膜下腔出血（SAH）（345.0 pg / ml，n = 20）的CSF NfH（SMI35）值高于参考人群（27.1 pg / ml，n = 73，每次比较p <0.0001）。结论：新的基于ECL的脑脊液NfH（SMI35）测定方法在灵敏度，精密度和准确性方面均优于以前发表的方法（Petzold等，2003; Shaw等，2005; Teunissen等，2009）。 。改进的性能和较小的样品量要求使该方法在实验设置和临床试验中合格，旨在对有限数量的材料进行大量测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号